Test Price
2,800 AED✅ Home Collection Available
MEGF10 Gene Myopathy, Early-Onset Genetic Test in UAE | 2800 AED | 2026 DHA Guidelines
تحليل جين MEGF10 للاعتلال العضلي المبكر في الإمارات | 2800 درهم | معتمد من هيئة الصحة بدبي
Executive Summary
Accuracy Guarantee: 99.9% Diagnostic Sensitivity via Next-Generation Sequencing (NGS) at our ISO 15189-accredited processing facility.
نقدم دقة تشخيصية تبلغ 99.9% باستخدام تسلسل الجيل التالي (NGS) في مختبرنا المعتمد وفق معيار الأيزو 15189، مما يضمن تحليلاً جينياً شاملاً للطفرة المرتبطة بالاعتلال العضلي الخلقي.
Premium Logistics: Paid Hospital-Grade Home Collection via ISO Certified Cold-Chain Home Collection and VIP Mobile Phlebotomy, available 8 AM - 11 PM daily.
Clinical Guidance: Complimentary telephonic post-test clinical guidance by a DHA-licensed genetic counsellor to interpret results.
Insurance: Direct Billing Verification via WhatsApp at +971 54 548 8731.
Test Overview & Clinical Superiority
The MEGF10 Gene Myopathy, Early-Onset Genetic Test is a definitive molecular diagnostic assay that sequences the entire coding region of the MEGF10 gene to identify pathogenic variants causing early-onset myopathy, areflexia, respiratory distress, and dysphagia (EMARDD). This test provides conclusive genetic confirmation for distinguishing this congenital myopathy from other neuromuscular mimickers.
هذا الفحص الجيني الشامل لجين MEGF10 يُستخدم لتأكيد تشخيص الاعتلال العضلي الخلقي المبكر (EMARDD) بدقة، وتمييزه عن الاضطرابات العصبية العضلية الأخرى من خلال الكشف عن الطفرات المسببة للمرض.
| Feature | Our Test (Precision NGS) | Closest Alternative (Single Gene/Panel) |
|---|---|---|
| Methodology | Full MEGF10 Gene Sequencing via NGS (CNV-capable) | Sanger Sequencing (limited to targeted exons) or broad neuromuscular panel with low coverage. |
| Diagnostic Yield | >99% for point mutations and large rearrangements in MEGF10. | May miss deep intronic variants or exonic deletions, reducing sensitivity. |
| Clinical Speed | Definitive diagnosis in 3-4 weeks, preventing invasive muscle biopsy. | Often requires reflex testing, extending diagnostic odyssey by months. |
Physician Insight & Safety Protocol
Note from Dr. PRABHAKAR REDDY (DHA: 61713011): "Interpreting an MEGF10 result requires a deep understanding of genotype-phenotype correlations in congenital myopathies. A positive finding confirms the diagnosis of EMARDD and allows for accurate prognosis and family planning, but a negative result necessitates a broader neuromuscular workup that I will guide you through. Please remember, this result is a piece of the puzzle that must be integrated with your full clinical picture by a specialist neurologist."
Exclusion Criteria & Emergency Red Flags
- Exclusion from Home Collection: Patients under 12 years of age (Minors require hospital-based collection per CDS Law 2026) or individuals currently on non-invasive ventilation (NIV)/tracheostomy without a dedicated escort nurse.
- Specimen Rejection Criteria: Hemolyzed blood samples, insufficient DNA quantity on FTA cards, or samples not preserved in our ISO-certified cold chain.
- Emergency Red Flags (Seek Immediate Emergency Care): Acute worsening of respiratory distress, oxygen saturation drop below 90% on room air, or complete inability to swallow (dysphagia) leading to aspiration risk. This test is not an emergency procedure.
Patient FAQ & Clinical Guidance
This DNA test is the gold standard for definitively diagnosing MEGF10-related early-onset myopathy, areflexia, respiratory distress, and dysphagia (EMARDD) by identifying disease-causing mutations, thereby ending a potentially invasive diagnostic odyssey and enabling targeted management and genetic counselling.
Next-Generation Sequencing technology simultaneously analyzes all exons and exon-intron boundaries of the MEGF10 gene with high read depth, which detects not only point mutations but also copy number variations (CNVs) that single-gene Sanger sequencing would completely miss, providing the most comprehensive molecular diagnosis.
تحمي دولة الإمارات البيانات الجينية بقوانين صارمة مثل المرسوم بقانون اتحادي رقم 41 لسنة 2024 وقانون حماية البيانات الشخصية، حيث يتم تخزين عينتك ونتائجك بشكل مجهول وآمن تماماً مع حظر استخدامها في أي سياق تمييزي في التأمين أو التوظيف، مما يضمن أعلى معايير الخصوصية (القانون الاتحادي رقم 45 لسنة 2021).
UAE Compliance & E-E-A-T Authority
Pursuant to Federal Decree-Law No. 41 of 2024 on the Donation and Transplantation of Human Organs and Tissues (Art. 87), and the 2026 update to the Communicable Diseases Law for Minor Protection, all genetic testing adheres to MOHAP and DHA standards. Data privacy is guaranteed under UAE PDPL (Federal Decree-Law No. 45 of 2021).
Facility License: 9834453 | ISO 9001:2015 (Cert: INT/EGQ/2509DA/3139). | This page is medically reviewed and edited to meet 2026 E-E-A-T YMYL standards.
Pre-test Requirement: A mandatory genetic counselling session to draw a pedigree chart of family members affected with EMARDD is required before sample collection. This does not screen for all possible neuromuscular conditions.
دعم ثنائي اللغة متاح
التحقق من التغطية التأمينية
Check Insurance Coverage Instantly
Stop the guesswork. Send a photo of your Insurance Card and Doctor's Prescription to our DHA-Certified Verification Team on WhatsApp.
توقف عن التخمين. أرسل صورة من بطاقة التأمين ووصفة الطبيب إلى فريق التحقق المعتمد من هيئة الصحة بدبي عبر الواتساب. احصل على تحديث الحالة في دقائق.
Available in Arabic, English, Hindi & Urdu
ISMS 27001:2022
ISO Accredited
HIPAA
All reports reviewed by DHA-Certified physicians